Hepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21

Journal of Endocrinology

Volumn 226, Issue 3, 2015, Pages 207-217

  Camporez, João Paulo G ^a   Asrih, Mohamed ^b   Zhang, Dongyan ^a   Kahn, Mario ^a   Samuel, Varman T ^a   Jurczak, Michael J ^a   Jornayvaz, François R ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Energy expenditure; FGF21; insulin resistance; NAFLD; Obesity

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; GLUCOSE; GLYCOGEN; FIBROBLAST GROWTH FACTOR; GLUCAGON; GLUCOSE BLOOD LEVEL; LIPID;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; BROWN ADIPOSE TISSUE; CALORIC INTAKE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOPLASMIC RETICULUM STRESS; ENERGY EXPENDITURE; FAT MASS; FATTY ACID BLOOD LEVEL; FOOD INTAKE; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; GLYCOGEN LIVER LEVEL; GLYCOGEN SYNTHESIS; GLYCOGENOLYSIS; HYPERINSULINEMIA; IMMUNOBLOTTING; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; KETOGENIC DIET; LIPID LIVER LEVEL; LIPID METABOLISM; LIPOLYSIS; LOCOMOTION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; WHITE ADIPOSE TISSUE; ANIMAL; BIOSYNTHESIS; BLOOD; ENERGY METABOLISM; GENETICS; KNOCKOUT MOUSE; LIVER; METABOLISM; PHYSIOLOGY;

ANIMALS; BLOOD GLUCOSE; ENERGY METABOLISM; FIBROBLAST GROWTH FACTORS; GLUCAGON; GLUCONEOGENESIS; GLUCOSE; GLYCOGEN; INSULIN RESISTANCE; LIPIDS; LIVER; MALE; MICE; MICE, KNOCKOUT;

EID: 84944554813     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-15-0136     Document Type: Article

References (61)

1. Angulo P 2002 Nonalcoholic fatty liver disease. New England Journal of Medicine 346 1221-1231. (doi:10.1056/NEJMra011775)
2. Arafat AM, Kaczmarek P, Skrzypski M, Pruszynska-Oszmalek E, Kolodziejski P, Szczepankiewicz D, Sassek M, Wojciechowicz T, Wiedenmann B, Pfeiffer AF et al. 2013 Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis? Diabetologia 56 588-597. (doi:10.1007/s00125-012-2803-y)
3. Arner P, Pettersson A,Mitchell PJ, Dunbar JD, Kharitonenkov A & RydenM 2008 FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity. FEBS Letters 582 1725-1730. (doi:10.1016/j.febslet.2008.04.038)
4. Asrih M & Jornayvaz FR 2013 Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. Journal of Endocrinology 218 R25-R36. (doi:10.1530/JOE-13-0201)
5. Asrih M & Jornayvaz FR 2015 Metabolic syndrome and nonalcoholic fatty liver disease: is insulin resistance the link? Molecular and Cellular Endocrinology [in press]. (doi:10.1016/j.mce.2015.02.018)
6. Asrih M, Altirriba J, Rohner-Jeanrenaud F & Jornayvaz FR 2015 Ketogenic diet impairs FGF21 signaling and promotes differential inflammatory responses in the liver and white adipose tissue. PLoS ONE 10 e0126364. (doi:10.1371/journal.pone.0126364)
7. Ayala JE, Samuel VT, Morton GJ, Obici S, Croniger CM, Shulman GI, Wasserman DH & McGuinness OP 2010 Standard operating procedures for describing and performingmetabolic tests of glucose homeostasis in mice. Disease Models & Mechanisms 3 525-534. (doi:10.1242/dmm. 006239)
8. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS & Maratos-Flier E 2007 Hepatic fibroblast growth factor 21 is regulated by PPARa and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metabolism 5 426-437. (doi:10.1016/j.cmet.2007.05.002)
9. Badman MK, Koester A, Flier JS, Kharitonenkov A & Maratos-Flier E 2009 Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150 4931-4940. (doi:10.1210/en. 2009-0532)
10. Berglund ED, Li CY, Bina HA, Lynes SE, Michael MD, Shanafelt AB, Kharitonenkov A & Wasserman DH 2009 Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 150 4084-4093. (doi:10.1210/en.2009-0221)
11. Birkenfeld AL, Lee HY, Guebre-Egziabher F, Alves TC, JurczakMJ, Jornayvaz FR, Zhang D, Hsiao JJ, Martin-Montalvo A, Fischer-Rosinsky A et al. 2011 Deletion of the mammalian INDY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in mice. Cell Metabolism 14 184-195. (doi:10.1016/j.cmet. 2011.06.009)
12. Bligh EG & Dyer WJ 1959 A rapid method of total lipid extraction and purification. Canadian Journal of Biochemistry and Physiology 37 911-917. (doi:10.1139/o59-099)
13. Camporez JP, Jornayvaz FR, Petersen MC, Pesta D, Guigni BA, Serr J, Zhang D, Kahn M, Samuel VT, Jurczak MJ et al. 2013 Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology 154 3099-3109. (doi:10.1210/en.2013-1191)
14. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA & Tripathy D 2009 Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 32 1542-1546. (doi:10.2337/dc09-0684)
15. Choi CS, Savage DB, Kulkarni A, Yu XX, Liu ZX, Morino K, Kim S, Distefano A, Samuel VT, Neschen S et al. 2007 Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. Journal of Biological Chemistry 282 22678-22688. (doi:10.1074/jbc.M704213200)
16. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE & Kharitonenkov A 2008 Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149 6018-6027. (doi:10.1210/en.2008-0816)
17. Ding X, Boney-Montoya J, Owen BM, Bookout AL, Coate KC, Mangelsdorf DJ & Kliewer SA 2012 bKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metabolism 16 387-393. (doi:10.1016/j.cmet.2012.08.002)
18. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, Badman MK, Martinez-Chantar ML & Maratos-Flier E 2010 Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139 456-463. (doi:10.1053/j.gastro.2010. 04.054)
19. Fabbrini E, Sullivan S & Klein S 2010 Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51 679-689. (doi:10.1002/hep.23280)
20. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN et al. 2011 National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377 557-567. (doi:10.1016/S0140-6736(10)62037-5)
21. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS & Maratos-Flier E 2010 Obesity is a fibroblast growth factor 21 (FGF21)- resistant state. Diabetes 59 2781-2789. (doi:10.2337/db10-0193)
22. Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdeguer F, Wu J, Kharitonenkov A, Flier JS, Maratos-Flier E et al. 2012 FGF21 regulates PGC-1a and browning of white adipose tissues in adaptive thermogenesis. Genes and Development 26 271-281. (doi:10.1101/gad. 177857.111)
23. Flegal KM, Carroll MD, Ogden CL & Curtin LR 2010 Prevalence and trends in obesity among US adults, 1999-2008. Journal of the American Medical Association 303 235-241. (doi:10.1001/jama.2009.2014)
24. Gaich G, Chien JY, FuH,Glass LC, Deeg MA, Holland WL, Kharitonenkov A, Bumol T, Schilske HK & Moller DE 2013 The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metabolism 18 333-340. (doi:10.1016/j.cmet.2013.08.005)
25. Habegger KM, Stemmer K, Cheng C, Muller TD, Heppner KM, Ottaway N, Holland J, Hembree JL, Smiley D, Gelfanov V et al. 2013 Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 62 1453-1463. (doi:10.2337/db12-1116)
26. Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM, Liu Y, Narra K, Hoehn KL, Knotts TA, Siesky A et al. 2007 Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metabolism 5 167-179. (doi:10.1016/j.cmet.2007.01.002)
27. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman BT, Halberg N, Rutkowski JM et al. 2011 Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nature Medicine 17 55-63. (doi:10.1038/nm.2277)
28. Holland WL, Adams AC, Brozinick JT, Bui HH, Miyauchi Y, Kusminski CM, Bauer SM, Wade M, Singhal E, Cheng CC et al. 2013 An FGF21- adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metabolism 17 790-797. (doi:10.1016/j.cmet.2013. 03.019)
29. Hotamisligil GS 2006 Inflammation and metabolic disorders. Nature 444 860-867. (doi:10.1038/nature05485) Hotamisligil GS 2010 Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 140 900-917. (doi:10.1016/j.cell.2010. 02.034)
30. Hotta Y, Nakamura H, Konishi M, Murata Y, Takagi H, Matsumura S, Inoue K, Fushiki T & Itoh N 2009 Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 150 4625-4633. (doi:10.1210/en.2009-0119)
31. Jornayvaz FR & Shulman GI 2012 Diacylglycerol activation of protein kinase C3 and hepatic insulin resistance. Cell Metabolism 15 574-584. (doi:10.1016/j.cmet.2012.03.005)
32. Jornayvaz FR, Jurczak MJ, Lee HY, Birkenfeld AL, Frederick DW, Zhang D, Zhang XM, Samuel VT & Shulman GI 2010 A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gain. American Journal of Physiology. Endocrinology and Metabolism 299 E808-E815. (doi:10.1152/ajpendo. 00361.2010)
33. Jornayvaz FR, Birkenfeld AL, Jurczak MJ, Kanda S, Guigni BA, Jiang DC, Zhang D, Lee HY, Samuel VT & Shulman GI 2011 Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. PNAS 108 5748-5752. (doi:10.1073/pnas. 1103451108)
34. Jornayvaz FR, Lee HY, Jurczak MJ, Alves TC, Guebre-Egziabher F, Guigni BA, Zhang D, Samuel VT, Silva JE & Shulman GI 2012 Thyroid hormone receptor-a gene knockout mice are protected from diet-induced hepatic insulin resistance. Endocrinology 153 583-591. (doi:10.1210/en.2011- 1793)
35. Kharitonenkov A & Larsen P 2011 FGF21 reloaded: challenges of a rapidly growing field. Trends in Endocrinology and Metabolism 22 81-86. (doi:10.1016/j.tem.2010.11.003)
36. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA et al. 2005 FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation 115 1627-1635. (doi:10.1172/JCI23606)
37. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB & Etgen GJ 2007 The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148 774-781. (doi:10.1210/en.2006-1168)
38. Kliewer SA & Mangelsdorf DJ 2010 Fibroblast growth factor 21: from pharmacology to physiology. American Journal of Clinical Nutrition 91 254S-257S. (doi:10.3945/ajcn.2009.28449B)
39. Kong LJ, Feng W, Wright M, Chen Y, Dallas-yang Q, Zhou YP & Berger JP 2013 FGF21 suppresses hepatic glucose production through the activation of atypical protein kinase Ci/l. European Journal of Pharmacology 702 302-308. (doi:10.1016/j.ejphar.2012.11.065)
40. Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, Chu X, Still CD, Gerhard GS, Han X, Dziura J et al. 2011 Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. PNAS 108 16381-16385. (doi:10.1073/pnas.1113359108)
41. Laeger T, Henagan TM, Albarado DC, Redman LM, Bray GA, Noland RC, Munzberg H, Hutson SM, Gettys TW, SchwartzMWet al. 2014 FGF21 is an endocrine signal of protein restriction. Journal of Clinical Investigation 124 3913-3922. (doi:10.1172/JCI74915)
42. Li X, Ge H, Weiszmann J, Hecht R, Li YS, Veniant MM, Xu J, Wu X, Lindberg R & Li Y 2009 Inhibition of lipolysis may contribute to the acute regulation of plasma FFA and glucose by FGF21 in ob/ob mice. FEBS Letters 583 3230-3234. (doi:10.1016/j.febslet.2009.09.012)
43. Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, Zhang H, Pan X, Bao Y, Xiang K et al. 2010 Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. Journal of Hepatology 53 934-940. (doi:10.1016/j.jhep. 2010.05.018)
44. Li K, Li L, Yang M, Liu H, Boden G & Yang G 2012 The effects of fibroblast growth factor-21 knockdown and over-expression on its signaling pathway and glucose-lipid metabolism in vitro. Molecular and Cellular Endocrinology 348 21-26. (doi:10.1016/j.mce.2011.07.026)
45. Lin Z, Tian H, Lam KS, Lin S, Hoo RC, KonishiM, Itoh N, Wang Y, Bornstein SR, Xu A et al. 2013 Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metabolism 17 779-789. (doi:10.1016/j.cmet.2013.04.005)
46. Markan KR, Naber MC, Ameka MK, Anderegg MD, Mangelsdorf DJ, Kliewer SA, Mohammadi M & Potthoff MJ 2014 Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 63 4057-4063. (doi:10.2337/db14-0595)
47. Morris-Stiff G & Feldstein AE 2010 Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice. Journal of Hepatology 53 795-796. (doi:10.1016/j.jhep.2010.07.003)
48. Mu J, Pinkstaff J, Li Z, Skidmore L, Li N, Myler H, Dallas-Yang Q, Putnam AM, Yao J, Bussell S et al. 2012 FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 61 505-512. (doi:10.2337/db11-0838)
49. Muise ES, Souza S, Chi A, Tan Y, Zhao X, Liu F, Dallas-Yang Q, WuM, Sarr T, Zhu L et al. 2013 Downstream signaling pathways in mouse adipose tissues following acute in vivo administration of fibroblast growth factor 21. PLoS ONE 8 e73011. (doi:10.1371/journal.pone.0073011)
50. Murata Y, Nishio K, Mochiyama T, KonishiM, Shimada M, OhtaH & Itoh N 2013 Fgf21 impairs adipocyte insulin sensitivity in mice fed a low-carbohydrate, high-fat ketogenic diet. PLoS ONE 8 e69330. (doi:10.1371/journal.pone.0069330)
51. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH & Hotamisligil GS 2004 Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306 457-461. (doi:10.1126/science.1103160)
52. Pfaffl MW 2001 A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research 29 e45. (doi:10.1093/nar/29. 9.e45)
53. Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, Goetz R, Mohammadi M, Finck BN, Mangelsdorf DJ, Kliewer SA et al. 2009 FGF21 induces PGC-1a and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. PNAS 106 10853-10858. (doi:10.1073/ pnas.0904187106)
54. Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, Zhang XM, Monia BP, Bhanot S & Shulman GI 2007 Inhibition of protein kinase C3 prevents hepatic insulin resistance in nonalcoholic fatty liver disease. Journal of Clinical Investigation 117 739-745. (doi:10.1172/JCI30400)
55. Samuel VT, Beddow SA, Iwasaki T, Zhang XM, Chu X, Still CD, Gerhard GS & Shulman GI 2009 Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with type 2 diabetes. PNAS 106 12121-12126. (doi:10.1073/pnas.0812547106)
56. Samuel VT, Petersen KF & Shulman GI 2010 Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375 2267-2277. (doi:10.1016/S0140-6736(10)60408-4)
57. Schaap FG, Kremer AE, Lamers WH, Jansen PL & Gaemers IC 2013 Fibroblast growth factor 21 is induced by endoplasmic reticulum stress. Biochimie 95 692-699. (doi:10.1016/j.biochi.2012.10.019) Shulman GI 2000 Cellular mechanisms of insulin resistance. Journal of Clinical Investigation 106 171-176. (doi:10.1172/JCI10583)
58. Wang Y, Solt LA & Burris TP 2010 Regulation of FGF21 expression and secretion by retinoic acid receptor-related orphan receptor a. Journal of Biological Chemistry 285 15668-15673. (doi:10.1074/jbc. M110.102160)
59. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL & Harrison SA 2011 Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140 124-131. (doi:10.1053/j.gastro. 2010.09.038)
60. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li YS, Lindberg RA et al. 2009 Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58 250-259. (doi:10.2337/db08-0392)
61. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ et al. 2002 Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)- associated phosphatidylinositol 3-kinase activity in muscle. Journal of Biological Chemistry 277 50230-50236. (doi:10.1074/jbc.M200958200)